Heberprot-P drug, developed by Cuba under the aim of being used for the treatment of patients with diabetic foot ulcerations in advanced stages, is registered by Korean authorities.

Another boost to the import of scientific products, acknowledged through Titter the vice-minister of Domestic Trade, Débora Rivas, who served as spokeswoman for the Center for the Genetic Engineering and Biotechnology(CIGB), institution where the drug was developed.

The President of BiocubaFarma Enterprises Group in the island, Eduardo Martínez, recently emphasized, that till now there is no other existent drug such as the Heberprot-P.

¨It has to be said the simplest way possible, but is a reality, this is the only drug that allows a diabetic patient end up with an amputation despite having stage 4 or late stages ulcerations in the Wagner scale¨, he said.

The Heberprot-p is administrated three-times a week on the ulceration, while the molecule is infiltrated by a shot. When granulation happens, that means, that the dead tissue disappears and a new one starts growing, the following doses are painful to the patient, explained.

That is the reason why we are working on developing new formulations in order to reduce the amount of times the patient goes to the clinic for being treated with the drug, he added.

¨Improving the Heberprot-P´s effectiveness is not easy due to it is highly effective¨, he stressed, ¨but it is expected that with the new pharmaceutical formulation higher results will be obtained which will outnumber the current drug in its current administration.

Marta Ayala, General Director of the CIGB, complimented the scientist collective that has worked for years in the development of some other applications of this product.

¨Progress is being made, and we intend the product to be locally used, straight to the laceration or by injectable ways, in order to improve the main active in the damaged area and diminish the amount of administrations¨.

Treatment for diabetic foot ulcer with Heberprot-P consists on the administration of 75, diluted in 5 milliliters of water for injection, three times a week, perilesional or intralesional.

The drug was conceived in 1994 and more than 300 000 patients has been benefited all over the world with it, while it is registered in 24 countries, among them, Russia, Ukraine, Kuwait, Argentina, Turkey, Vietnam, Mongolia and Colombia.

Taken from Prensa Latina